Serotype distribution and antimicrobial resistance of *Streptococcus pneumoniae* among children with acute otitis media in Marrakech, Morocco

Sara Amari1, Karima Warda1, Youssef El Kamouni1,2, Lamiae Arsalane1,2, Mohamed Bouskraoui1, Said Zouhair1,2

1Department of Medical Biology, Laboratory of Microbiology and Virology, Faculty of Medicine and Pharmacy, Cadi Ayyad University, Marrakesh, Morocco
2Laboratory of Bacteriology Virology, Avicenne Hospital Military, Marrakesh, Morocco
3Department of Pediatrics, Mohammed VI University Hospital, Marrakesh, Morocco

Received: November 2021, Accepted: January 2022

ABSTRACT

**Background and Objectives:** *Streptococcus pneumoniae* (*S. pneumoniae*) is one of the most frequent pathogens leading to a variety of clinical manifestations. The effects of *S. pneumoniae* carriage on acute otitis media (AOM) are poorly studied. The study aimed to assess the serotype’s distribution and antimicrobial susceptibility in children with AOM after the implementation of the pneumococcal conjugate vaccine (PCV) in Morocco.

**Materials and Methods:** We conducted a prospective study of AOM children aged 6 to 36 months who visited pediatric centers in Marrakesh between January to June 2018. Parents were asked to complete a questionnaire and a swab was collected from each child. The *S. pneumoniae* strains were further identified (Hemolysis, optochin sensitivity, and agglutination test), serogrouped (IMMULEX PNEUMOTEST agglutination test), serotyped (Real time PCR) and tested for antimicrobial susceptibility.

**Results:** The *S. pneumoniae* carriage rate was 49.7% (87/175). As estimated, non-vaccine serotypes (NVT) were most prevalent (51/63; 81%). The most frequent serotypes were 6C/6D (12.7%), 10 (9.5%), and 19B/19C (9.5%). The *S. pneumoniae* strains that were isolated showed a diminished susceptibility to penicillin G with a rate of 27.5%. Penicillin non-susceptible pneumococci (PNSP) was mostly associated with NVT. More than 90% of *S. pneumoniae* isolates were susceptible to chloramphenicol (97.5%), clindamycin (97.5%), erythromycin (97.5%), levofloxacin (97.5%), pristinamycin (97.5%), gentamicin (92.5%), and teicoplanin (92.5%).

**Conclusion:** Important nasopharyngeal carriage prevalence was reported among children with AOM. The study showed that new NVT are emerging, including 6C/6D and 10. Furthermore, susceptibility was significantly higher against all antibiotics tested except for penicillin G and amoxicillin.

**Keywords:** Otitis media; Preschool children; Colonization; *Streptococcus pneumoniae*; 10 valent pneumococcal vaccine; Serotyping; Antibacterial drug resistance

1 Corresponding author: Sara Amari, Ph.D. Department of Medical Biology, Laboratory of Microbiology and Virology, School of Medicine and Pharmacy, Cadi Ayyad University, Marrakesh, Morocco. Tel: +212-653052243 Fax: +212-2524432887 Email: sara.amari@edu.uca.ma

Copyright © 2022 The Authors. Published by Tehran University of Medical Sciences. This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International license (https://creativecommons.org/licenses/by-nc/4.0/). Noncommercial uses of the work are permitted, provided the original work is properly cited.
INTRODUCTION

Acute otitis media (AOM) continues to be among the most prevalent infectious diseases in early childhood worldwide (1). It is an inflammation of the middle ear characterized by a viscous effusion, fever, otalgia, otorrhea, and conjunctivitis (2, 3). Thus, AOM occurs most often in children aged less than 5 years and is a primary reason for pediatric consultations and antibiotic prescriptions (4). Predominant bacteria that cause AOM are *Haemophilus influenzae*, *Moraxella catarrhalis*, *Streptococcus pyogenes*, and *Streptococcus pneumoniae* (5). However, it is known that *S. pneumoniae* is the main cause of AOM in approximately half of the global cases (6-8).

Pneumococcal infections are usually preceded by asymptomatic colonization of the nasopharynx (9). According to the diversity of capsular types, *S. pneumoniae* is divided into 101 distinct serotypes, where only serotypes 6A, 6B, 14, 19A, 19F, and 23F are frequently associated with AOM (10-12). Indeed, pneumococcal vaccination remains an effective means against the pneumococcal serotypes causing AOM (13-16). The pneumococcal conjugate vaccines (PCV) have dramatically reduced the proportion of AOM episodes caused by *S. pneumoniae* in young children (17).

In Morocco, PCV13 (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) was introduced in the national immunization program (NIP) during 2010 and was later replaced by PCV10 (1, 4, 5, 6B, 7F, 9V, 14, 19F, 18C, and 23F) in July 2012. Following the implementation of these vaccines, no survey providing reliable epidemiological information on nasopharyngeal colonization among children suffering from AOM has been conducted. This study aimed to determine the colonization rate, the distribution of serotypes covered by PCV10, and the antibiotic resistance of *S. pneumoniae*, among AOM children, after PCV introduction.

MATERIALS AND METHODS

Study type and population. This prospective study was conducted from January to June 2018. Children who were aged 6-36 months and vaccinated against *S. pneumoniae* as well as admitted as outpatients by private pediatric centers in Marrakesh because of AOM were enrolled in this study. Each case was defined based on the presence of the following symptoms and signs: earache and fever during a common cold illness combined with otoscopic confirmation of bulging, opacification with congestion, or a perforated tympanic membrane. Children were excluded if they had taken antibiotics one week prior to the enrollment. A questionnaire containing demographic (age, gender, and type of childcare) and clinical (fever, conjunctivitis, earache, and ototorhea) information was completed for each patient. The child's immunization history was checked and recorded.

Specimen collection and processing. Nasopharyngeal specimens were collected using a sterile swab containing transport medium and transferred within 2h at 4-8°C to the Bacteriology-Virology Laboratory of the Avicenna military hospital in Marrakesh. Each swab was streaked on Colistin-Nalidixic Acid Agar supplemented with 5% of blood. The plates were incubated overnight at 37°C in a 5% CO₂ atmosphere.

Identification of *S. pneumoniae*. The pneumococcus isolates were preliminarily determined based on morphology, optochin susceptibility, and agglutination test (Slide pneumo-Kit Bio Mérieux) (18, 19). Every single alpha-hemolytic colony was selected from the primary culture and a secondary culture was prepared to obtain pure growth.

Serogrouping / serotyping. The detection of serogroup-type was first performed using the IMMULEX PNEUMOTEST agglutination test (Staten Serum Institut Copenhagen, Denmark) and secondly using the real–time polymerase chain reaction (RT-PCR) in conformity with the protocol and guidelines published by the Centers for Disease Control and Prevention (CDC). Isolates that showed no agglutination were classified as non-typeable.

Antimicrobial susceptibility testing. The antimicrobial sensitivity testing was performed using the disk diffusion method on Mueller Hinton agar (MHA) supplemented with 5% of sheep blood. The antimicrobials tested were tetracycline, erythromycin, clindamycin, gentamicin, levofloxacin, teicoplanin, vancomycin, pristinamycin, chloramphenicol, linezolid, and Trimethoprim-sulfamethoxazole (SXT). PNSP (Penicillin non-susceptible pneumococci) was detected using an oxacillin disk (OXA 5 μg, <20 mm). The minimal inhibitory concentrations (MICs) of peni-
cillin G, amoxicillin, cefepime, and cefotaxime were determined using the BD Phoenix System following the manufacturer’s protocol. The zone diameters of susceptibility testing were categorized as resistant, intermediate, or sensitive according to the European Committee on Antimicrobial Susceptibility Testing guidelines (EUCAST, 2018).

**Statistical analysis.** Statistical analysis was done using the SPSS/PC 23.0 program (SPSS Inc., Chicago, IL, USA). Logistic regression analyses were performed to identify risk factors for pneumococcal carriage among AOM children. Statistical significance was determined with 95% confidence intervals (CIs). The differences were considered significant if the p-value was less than 0.05.

**RESULTS**

During the study period, 175 children were diagnosed with AOM. The patient group included 91 (52%) males and 84 (48%) females. The mean age of our study population was 21.41 months. Clinically, 167 of patients (95.4%) presented with fever, 83 (47.4%) with conjunctivitis, 43 (24.6%) with otitis media, and 152 (86.9%) with otalgia. 25 (14.3%) had a history of prior AOM episodes. Bilateral AOM was recorded in 115 (65.7%) children. Of the total 175 AOM cases, 110 (62.9%) patients had been completely vaccinated, whereas 65 (37.1%) patients had received only two doses against *S. pneumoniae*. According to the questionnaire, 71 (40.6%) confirmed previous antibiotic treatment during the last three months.

**Pneumococcal carriage in children with AOM.** A total of 87 cultures were positive from the 175 samples collected, bringing the overall pneumococcal carriage to 49.7%. There was no significant difference in pneumococcal carriage between male and female groups (40/78, 51.2% and 47/97, 48.4% respectively, p=0.710). Young age was significantly associated with nasopharyngeal carriage of *S. pneumoniae* (6-11m: 35/58; 60.3%, 12-23m: 30/60; 50% and 24-36m: 22/55; 40%). Additionally, children having conjunctivitis exhibited lower pneumococcal colonization than normal children (p<0.05) (Table 1).

**Pneumococcal serotypes and PCV serotypes identified in carriage isolates.** Of the 63 pneumococcal carriage isolates serotyped, 22 different serotypes were identified. The most frequent of these being 6C/6D (n=8, 12.7%), 10 (n=6, 9.5%), and 19B/19C (n=6, 9.5%), followed by 21 (n=5, 7.9%), 23B (n=5, 7.9%), 14 (n=4, 6.3%), 15B/15C (n=4, 6.3%), 7C/7B/40 (n=3, 4.8%), 11A/11D (n=3, 4.8%), 7F (n=2, 3.2%), 15A/15F (n=2, 3.2%), 17F (n=2, 3.2%), 19F (n=2, 3.2%), 35A (n=2, 3.2%), 39 (n=2, 3.2%), 1 (n=1, 1.6%), 3 (n=1, 1.6%), 4 (n=1, 1.6%), 9V (n=1, 1.6%), 13 (n=1, 1.6%), 20 (n=1, 1.6%), and 23A (n=1, 1.6%) (Fig. 1). Overall, vaccine serotypes (VT) comprised 19% (12/63) of which serotype 3 (n=1) was the only PCV13 serotype, but not PCV10 serotypes, detected. On the other hand, non-vaccine serotypes (NVT) covered 81% (51/63) of the isolates. The most frequent NVT was 6C/6D (n=8) serotype.

**Antibiotic resistance of *S. pneumoniae* isolates.** Antibiotic resistance was tested among the 40 available isolates. The prevalence rate of PNSP was 27.5%, where 27.2% of them were highly resistant to penicillin G (MICs ≥ 2 mg/ml) and 72.8% were intermediate (CMI>0.06-1 mg/l). The prevalence rate of non-susceptibility to amoxicillin, tetracycline, and erythromycin was 63.6%, 54.5%, and 10%. Among the all strains tested, antimicrobial susceptibility pattern showed a high rate of antibiotic susceptibility to levofloxacin, erythromycin, clindamycin, pristinamycin, and chloramphenicol, 39 (97.5%) isolates each. All isolates were susceptible to vancomycin (100%). The non-susceptibility rates to teicoplanin, tetracycline and trimethoprim-sulfamethoxazole were 7.5%, 15%, and 12.5% respectively (Table 2).

**Serotype distribution of PNSP.** Among VTs, serotype 19F was the only VT identified as PNSP, whereas serotype 14 was totally susceptible to penicillin G. In Contrast, PNSP was mostly associated with NVTs. Of these, 6C/6D, 11A/11D, 13, 17F, 21, and 23A were the most common serotypes in PNSP, accounting for 37.5%, 100%, 100%, 50%, 50%, and 100% (Fig. 2).

**DISCUSSION**

The nasopharynx is a natural host to many commensals, such as *S. pneumoniae*, that occasionally can become pathogenic (20-22). AOM infection is generally induced by otropathogens rise from the nasal cavity to the middle ear (23, 24). Many stud-
Table 1. Univariate and multivariate logistic regression analysis of *S. pneumoniae* carriage among AOM children

| Characteristics                        | Colonized (n=87) | Non-colonized (n=88) | OR      | 95% CI      | P value |
|----------------------------------------|------------------|-----------------------|---------|-------------|---------|
| Age (months)                           |                  |                       |         |             |         |
| ≤12                                    | 35               | 23                    |         |             |         |
| 13-24                                  | 30               | 30                    | 1.522   | 0.733-3.158 | 0.260   |
| 25-36                                  | 22               | 35                    | 2.421   | 1.145-5.121 | 0.021   |
| Gender                                 |                  |                       |         |             |         |
| Male                                   | 40               | 38                    | 1.058   | 0.785-1.426 | 0.710   |
| Female                                 | 47               | 50                    |         |             |         |
| Siblings                               | 64               | 54                    | 0.744   | 0.301-1.084 | 0.085   |
| Preschool attendance                   | 44               | 7                     | 0.402   | 0.308-0.524 | <0.001 |
| Signs and symptoms                     |                  |                       |         |             |         |
| Fever                                  | 83               | 80                    | 1.528   | 0.677-3.448 | 0.240   |
| Conjunctivitis                         | 20               | 53                    | 1.417   | 0.280-6.227 | <0.001 |
| Otorrhea                               | 22               | 20                    | 1.072   | 0.765-1.501 | 0.692   |
| Otalgia                                | 77               | 74                    | 1.224   | 0.743-2.015 | 0.396   |
| Bilateral AOM                          | 65               | 52                    | 0.694   | 0.501-0.961 | 0.028   |
| Prior antibiotic use (<3 months)       | 46               | 53                    | 0.861   | 0.640-1.158 | 0.326   |

Fig. 1. Serotype distribution of nasopharyngeal *S. pneumoniae* isolated from children with AOM in Marrakesh, Morocco

Studies have reported the concordance between the nasopharyngeal carriage of *S. pneumoniae* and AOM (25-29). In this study of pneumococcal carriage in children suffering from AOM, the colonization rate of *S. pneumoniae* was 49.7%. Colonization rate of *S. pneumoniae* vary between studies from 40.5% to 68.3% (30-32). The colonization rate in the current study is in the middle of the reported range, as in this study we recruited AOM children that are supposed to have an important colonization rate (33, 34). Ekincci et al. (2021) demonstrated an overall pneumococcal colonization rate of 79.2% among AOM children after the introduction of PCV10 (26). Furthermore, Cohen et al. showed that the pneumococcal colonization prevalence has significantly reduced from 71.2% to 56.2% from 2001 to 2014 in France (35). Before
the introduction of PCV in Vietnam, *S. pneumoniae* colonization was about 35%, in 2016 (25). The Colonization rates of *S. pneumoniae* vary between studies according to many factors including population age, vaccination status, study period, inclusion criteria, and identification method (35-37).

After PCV13 was introduced to the Moroccan NIP in 2010, and was switched to PCV10 in July 2012, there was a significant drop in invasive pneumococcal disease where NVTs were mostly the major cause (31, 38). In our study, 19% of *S. pneumoniae* strains were VT, and 81% were NVT. These results provide additional evidence for how vaccine can reduce VTs. Within this study, the most frequent serotypes were 6C/6D, 10, 19B/19C, 21, 23B, 15B/15C, 7C/7B/40, 11A/11D, 15A/15F, 17F, 35A, 39, 13, 20, and 23A. Of the evaluated non-PCV serotypes, 6C/6D was the most frequent, 10 and 19B/19C were the second, and 21 and 23B were the third most common serotypes. In Setchanova et al.’s study that involved 198 children with severe AOM, they showed that PCV10 coverage rate accounted for 40% (39). In Chi et al.’s study, the serotype coverage prevalence for PCV10 was 9.1% among patients aged 0 to 18 years (40).

**Table 2.** Antimicrobial susceptibility rate of nasopharyngeal isolates among AOM children in Marrakesh, Morocco

| Antimicrobial agents          | N=40 | Susceptible | Intermediate resistant | Resistant |
|-------------------------------|------|-------------|------------------------|-----------|
| Penicillin G                  | 29   | (72.5%)     | 8 (20%)                | 3 (7.5%)  |
| Amoxicillin                   | 33   | (82.5%)     | 2 (5%)                 | 5 (12.5%) |
| Cefepim                       | 36   | (90%)       | 1 (2.5%)               | 3 (7.5%)  |
| Cefotaxime                    | 33   | (82.5%)     | 4 (10%)                | 3 (7.5%)  |
| Tetracycline                  | 34   | (85%)       | 6 (15%)                | -         |
| Levofloxacin                  | 39   | (97.5%)     | 1 (2.5%)               | -         |
| Gentamycin-Syn                | 37   | (92.5%)     | 3 (7.5%)               | -         |
| Teicoplanin                   | 37   | (92.5%)     | 3 (7.5%)               | -         |
| Vancomycin                    | 40   | (100%)      | -                      | -         |
| Erythromycin                  | 39   | (97.5%)     | 1 (2.5%)               | -         |
| Clindamycin                   | 39   | (97.5%)     | 1 (2.5%)               | -         |
| Pristinamycin                 | 39   | (97.5%)     | 1 (2.5%)               | -         |
| Chloramphenicol               | 39   | (97.5%)     | 1 (2.5%)               | -         |
| Trimethoprim-Sulfamethoxazole | 35   | (87.5%)     | 5 (12.5%)              | -         |

**Fig. 2.** Penicillin susceptibility of nasopharyngeal *S. pneumoniae* by serotype among children with AOM.
Nevertheless, it is noticeable that VTs may be detected among AOM cases. In our study, we noted that all VTs were included in PCV10, except for serotype 3 which is included in PCV13. This is in line with Allemann et al.’s study that showed the persistence of serotype 3 even in the PCV 13 era (16). Similar to our data, a relatively important drop of VTs isolated from the middle ear specimens, and a significant increase in the prevalence of NVT was demonstrated after the generalization of PCV in Iceland (13).

Within this study, the frequency of PNSP was 27.5% among AOM children. Increasing rate of PNSP may be the main cause of failure of antibiotic treatment in AOM children (28). A high level of PNSP strains was reported by other authors in asymptomatic carriage and pneumococcal disease (29, 39, 41-43). Furthermore, 18.5% of *S. pneumoniae* strains were resistant to amoxicillin. This finding may be because penicillin G and amoxicillin are the first-line treatment. In addition, 90% and 82.5% of *S. pneumoniae* isolates are still susceptible to cefepime and cefotaxime. Our findings have confirmed recent reports confirming that PNSP was mostly associated with serotypes not targeted by the vaccine (44-46). Serotypes 6C, 19F, and 11A have been the subject of concern in many studies due to penicillin non-susceptibility (36, 41, 47). Further studies are recommended to comment on the clinical impact of antimicrobial resistance of these serotypes in Morocco.

The overall non-susceptibility prevalence of *S. pneumoniae* to erythromycin, clindamycin, pristinamycin, tetracycline, chloramphenicol, and trimethoprim-sulfamethoxazole was 2.5%, 2.5%, 2.5%, 15%, 2.5%, and 12.5%, respectively. The non-susceptibility to erythromycin was lower than studies accomplished in Argentina (26.6%) (48), in Oman (28.1%) (49), in Iran (71.4%) (50), and in Taiwan (80%) (51). Two and a half percent (2.5%) isolates were resistant to clindamycin. Higher clindamycin resistance prevalences were observed in Oman (16.7%) (49), in Taiwan (77%) (51), and in Shanghai (97%) (52). Furthermore, 2.5% of our pneumococci strains were non-susceptible to pristinamycin, which is higher than a survey conducted in Morocco (0%) before introduction of pneumococcal vaccination (30). In addition, non-susceptibility to tetracycline was 15% in our study. Important non susceptibility prevalences were reported in Indonesia (44%) (53), in Iran (66.9%) (50), and in Taiwan (80%) (51). Furthermore, 2.5% of our pneumococci strains were non-suscep-tible to chloramphenicol, which is comparable to 0.1% in Argentina (48), but lower than in Indonesia (9.7%) (54), and in Tanzania (18.4%) (55). Twelve and a half percent (12.5%) of our *S. pneumoniae* isolates were resistant to trimethoprim-sulfamethoxazol. High rates of non-susceptibility to trimethoprim-sulfamethoxazol was found in Indonesia (29.7%) (54), in Japan (37.9%) (56), in Iran (57.1%) (50), and in Shanghai (75.3%) (52). The rate of antimicrobial non-susceptibility differs greatly across countries depending on many factors such as age, nature of specimens, vaccination era, and antimicrobial consumption.

A limitation of this study was that we have only collected nasopharyngeal swabs from children suffering from AOM. We have not collected middle ear fluid specimens because of limited facilities available for the collection of middle ear fluid. Another limitation includes the fact that the enrollment in a private pediatric setting in Marrakesh, Morocco where the children enrolled might not represent the entire Moroccan pediatric population. In addition, similar research should be held, in different regions of Morocco, to evaluate the impact of pneumococcal vaccination against AOM.

**CONCLUSION**

In conclusion, the present study provides new baseline data on the nasopharyngeal carriage of *S. pneumoniae* among children suffering from AOM in Marrakesh, Morocco. It suggests that new VTs are emerging, including 6C/6D and 10. Furthermore, it provides a relevant result, such as the spread of PNSP among AOM children. Pneumococcal carriage is an important determinant of the spread of new serotypes and antibiotic resistance, despite the efficacy of PCV10 in reducing the emergence of VT.

**ACKNOWLEDGEMENTS**

We thank the director of the Moroccan Society for Pediatric Infectiology and Vaccinology (SOMIVEP). We also thank the responsible and the staff members of the Laboratory of Microbiology of the Military Hospital Avicenna and laboratory of Microbiology-virology of the Faculty of Medicine and Pharmacy of Marrakesh for their technical support.
REFERENCES

1. Schilder AGM, Chonmaitree T, Cripps AW, Rosenfeld RM, Casselbrant ML, Haggard MP, et al. Otitis media. *Nat Rev Dis Primers* 2016; 2: 16063.

2. Jepsersen SI, Demant MN, Pedersen ML, Homse P. Acute otitis media and pneumococcal vaccination—an observational cross-sectional study of otitis media among vaccinated and unvaccinated children in Greenland. *Int J Circumpolar Health* 2021; 80: 1858615.

3. Avnstorp MB, Homse P, Bjerregaard P, Jensen RG. Chronic supplicative otitis media, middle ear pathology and corresponding hearing loss in a cohort of Greenlandic children. *Int J Pediatr Otorhinolaryngol* 2016; 83: 148-153.

4. Suaya JA, Gessner BD, Fung S, Vuocolo S, Scaife J, Swebold DL, et al. Acute otitis media, antimicrobial prescriptions, and medical expenses among children in the United States during 2011–2016. *Vaccine* 2018; 36: 7479-7486.

5. Ngo CC, Massa HM, Thornton RB, Cripps AW. Predominant bacteria detected from the middle ear fluid of children experiencing otitis media: A systematic review. *PLoS One* 2016; 11(3): e0150949.

6. Imohl M, Perniciaro S, Busse A, van der Linden M. Bacterial spectrum of spontaneously ruptured otitis media in a 7-year, longitudinal, multicenter, epidemiological cross-sectional study in Germany. *Front Med (Lausanne)* 2021; 8: 675225.

7. Bergenguelz C, Hakansson AP. *Streptococcus pneumoniae* Otitis Media pathogenesis and how it informs our understanding of vaccine strategies. *Curr Otorhinolaryngol Rep* 2017; 5: 115-124.

8. Loughran AJ, Orihuela CJ, Tuomanen EI. *Streptococcus pneumoniae*: invasion and inflammation. *Microbiol Spectr* 2019; 7: 10.1128/microbiolspec.GPP3-0004-2018.

9. Howard LM, Zhu Y, Griffin MR, Edwards KM, Williams J V, Gil AI, et al. Nasopharyngeal Pneumococcal density during asymptomatic respiratory virus infection and risk for subsequent acute respiratory illness. *Emerg Infect Dis* 2019; 25: 2040-2047.

10. Littorin N, Ahl J, Uddén F, Resman F, Riesbeck K. Reduction of *Streptococcus pneumoniae* in upper respiratory tract cultures and a decreased incidence of related acute otitis media following introduction of childhood pneumococcal conjugate vaccines in a Swedish county. *BMC Infect Dis* 2016; 16: 407.

11. Ganaie F, Saad JS, McGee L, van Tonder AJ, Bentley SD, Lo SW, et al. A new pneumococcal capsule type, 10D, is the 100th serotype and has a large cps fragment from an oral streptococcus. *mBio* 2020; 11(3): e00937-20.

12. Ganaie F, Maruhn K, Li C, Porambo RJ, Elverdal PL, Abeygunawardana C, et al. Structural, genetic, and serological elucidation of *Streptococcus pneumoniae* serogroup 24 serotypes: discovery of a new serotype, 24C, with a variable capsule structure. *J Clin Microbiol* 2021; 59(7): e0054021.

13. Quirk SJ, Haraldsson G, Erlendsdóttir H, Hjálmarsdóttir MA, van Tonder AJ, Hrafnskellsson B, et al. Effect of vaccination on pneumococci isolated from the nasopharynx of healthy children and the middle ear of children with otitis media in Iceland. *J Clin Microbiol* 2018; 56(12): e01046-18.

14. Soysal A, Günüllü E, Yildiz I, Aydemir G, Tunç T, Pirat Y, et al. Impact of the 13-valent pneumococcal conjugate vaccine on the incidences of acute otitis media, recurrent otitis media and tympanostomy tube insertion in children after its implementation into the national immunization program in Turkey. *Hum Vaccin Immunother* 2020; 16: 445-451.

15. Wouters I, Van Heirstraeten L, Desmet S, Blaizot S, Verhaegen J, Goossens H, et al. Nasopharyngeal *S. pneumoniae* carriage and density in Belgian infants after 9 years of pneumococcal conjugate vaccine programme. *Vaccine* 2018; 36: 15-22.

16. Allemann A, Frey PM, Brugger SD, Hilty M. Pneumococcal carriage and serotype variation before and after introduction of pneumococcal conjugate vaccines in patients with acute otitis media in Switzerland. *Vaccine* 2017; 35: 1946-1953.

17. Sigurdsson S, Eythorsson E, Hrafnskellsson B, Erlendsdóttir H, Kristinsson KG, Haraldsson A. Reduction in all-cause acute otitis media in children <3 years of age in primary care following vaccination with 10-valent Pneumococcal *Haemophilus influenzae* protein-D conjugate vaccine: a whole-population study. *Clin Infect Dis* 2018; 67: 1213-1219.

18. Altun O, Athlin S, Almuhayawi M, Strålin K, Özeni V. Rapid identification of *Streptococcus pneumoniae* in blood cultures by using the ImmuLex, SlideX and Wellcogen latex agglutination tests and the BinaxNOW antigen test. *Eur J Clin Microbiol Infect Dis* 2016; 35: 579-585.

19. Dubois D, Segonds C, Prere MF, Marty N, Oswald E. Identification of clinical *Streptococcus pneumoniae* isolates among other alpha and nonhemolytic Streptococci by use of the Vitek MS matrix-assisted laser desorption ionization – time of flight mass. *J Clin Microbiol* 2013; 51: 1861-1867.

20. Bosch AA, Biesbroek G, Trzcinski K, Sanders EA, Bogaert D. Viral and bacterial interactions in the upper respiratory tract. *PLoS Pathog* 2013; 9(1): e1003057.

21. Li N, Ma WT, Pang M, Fan QL, Hua JL. The commensal microbiota and viral infection: a comprehensive review. *Front Immunol* 2019; 10: 1551.

22. Ribet D, Cossart P. How bacterial pathogens colonize...
their hosts and invade deeper tissues. *Microbes Infect* 2015; 17: 173-183.

23. Enoksson F, Rodriguez AR, Peno C, Lopez CB, Tjernström F, Bogaert D, et al. Niche- and gender-dependent immune reactions in relation to the microbiota profile in pediatric patients with otitis media with effusion. *Infect Immun* 2020; 88(10): e00147-20.

24. Brugger SD, Kraemer JG, Wi B, Bomar L, Opplier A, and Hilty M. Age-Dependent dissimilarity of the nasopharyngeal and middle ear microbiota in children with acute otitis media. *Front Genet* 2019; 10: 555.

25. Satoh C, Toizumi M, Nguyen HAT, Hara M, Bui MX, Iwasaki C, et al. Prevalence and characteristics of children with otitis media with effusion in Vietnam. *Vaccine* 2021; 39: 2613-2619.

26. Ekinic E, Desmet S, Van Heirstraeten L, Mertens C, Wouters I, Beutels P, et al. *Streptococcus pneumoniae* serotypes carried by young children and their association with acute otitis media during the period 2016-2019. *Front Pediatr* 2021; 9: 664083.

27. Lee J, Kim KH, Jo DS, Ma SH, Kim JH, Kim CS, et al. A longitudinal hospital-based epidemiology study to assess acute otitis media incidence and nasopharyngeal carriage in Korean children up to 24 months. *Hum Vaccin Immunother* 2020; 16: 3090-3097.

28. Korona-głowniak I, Zychowski P, Siwiec R, Mazur E, Niedzielska G, Malm A. Resistant *Streptococcus pneumoniae* strains in children with acute otitis media – high risk of persistent colonization after treatment. *BMC Infect Dis* 2018; 18: 478.

29. Falup-Pecurariu O, Leibovitz E, Mercas A, Bleotu L, Zavaráche C, Porat N, et al. Pneumococcal acute otitis media in infants and children in central Romania, 2009-2011: microbiological characteristics and potential coverage by pneumococcal conjugate vaccines. *Int J Infect Dis* 2013; 17(9): e702-e706.

30. Warda K, Oufdou K, Zahlane K, Bouskraoui M. Antibiotic resistance and serotype distribution of nasopharyngeal isolates of *Streptococcus pneumoniae* from children in Marrakech region (Morocco). *J Infect Public Health* 2013; 6: 473-481.

31. Dilagui I, Moussair FZ, Loqman S, Diawara I, Zerouali K, Belabbes H, et al. *Streptococcus pneumoniae* carriage among febrile children at the time of PCV-10 immunization in pediatric emergencies at Mohammed VI university hospital centre in Marrakesh (Morocco). *Arch Pédiatr* 2019; 26: 453-458.

32. Jroundi I, Mahraoui C, Bennessaoud R, Moraleda C, Munoz Almagro C, Seffar M, et al. *Streptococcus pneumoniae* carriage among healthy and sick pediatri- cians patients before the generalized implementation of the 13-valent pneumococcal vaccine in Morocco from 2010 to 2011. *J Infect Public Health* 2017; 10: 165-170.

33. Brotons P, Bassat Q, Lanasa M, Henares D, Perez-ar- guello A, Madrid L, et al. Nasopharyngeal bacterial load as a marker for rapid and easy diagnosis of invasive pneumococcal disease in children from Mozambique. *PLoS One* 2017; 12(9): e0184762.

34. Baggett HC, Watson NL, Knoll MD, Brooks WA, Feikin DR, Hammitt LL, et al. Density of upper respira- tory colonization with *Streptococcus pneumoniae* and its role in the diagnosis of Pneumococcal Pneu- monia among children aged < 5 years in the perch study. *Clin Infect Dis* 2017; 64(suppl_3): S317–S327.

35. Cohen R, Varon E, Doit C, Schlemmer C, Romain O, Thollet F, et al. A 13-year survey of pneumococcal nasopharyngeal carriage in children with acute otitis media following PCV7 and PCV13 implementation. *Vaccine* 2015; 33: 5118-126.

36. Ziane H, Managero V, Ferreira E, Moura IB, Bektache S, Tazir M, et al. Serotypes and antibiotic susceptibili- ty of *Streptococcus pneumoniae* isolates from invasive Pneumococcal disease and asymptomatic carriage in a pre-vaccination Period, in Algeria. *Front Microbiol* 2016; 7:803.

37. Haile AA, Gidebo DD, Ali MM. Colonization rate of *Streptococcus pneumoniae*, its associated factors and antimicrobial susceptibility pattern among children attending kindergarten school in Hawassa, southern Ethiopia. *BMC Res Notes* 2019; 12: 344.

38. Diawara I, Zerouali K, Katly F, Zaki B, Belabbes H, Najib J, et al. Invasive pneumococcal disease among children younger than 5 years of age before and after introduction of pneumococcal conjugate vaccine in Casablanca, Morocco. *Int J Infect Dis* 2015; 40: 95-101.

39. Setchanova L, Murdjeva M, Stancheva I, Alexandrova A, Sredkova M, Stoeva T, et al. Serotype changes and antimicrobial nonsusceptibility rates of invasive and non-invasive *Streptococcus pneumoniae* isolates after implementation of 10-valent pneumococcal nontypea- ble *Haemophilus influenzae* protein D conjugate vac- cine (PHıD-CV) in Bulgaria. *Braz J Infect Dis* 2017; 21: 433-440.

40. Chi H, Chiu NC, Huang FY, Hsu CH, Lee KS, Huang LM, et al. Acute otitis media caused by *Streptococcus pneumoniae* serotype 19A ST320 clone: epidemiolog- ical and clinical characteristics. *J Microbiol Immunol Infect* 2018; 51: 337-343.

41. Pinto TCA, Neves FPG, Souza ARV, Oliveira LMA, Costa NS, Castro LFS, et al. Evolution of penicillin non-susceptibility among *Streptococcus pneumoniae* isolates recovered from asymptomatic carriage and invasive disease over 25 years in Brazil, 1990–2014. *Front Microbiol* 2019; 10: 486.

42. Engård M, Matsu SE, Nyombi BM, Mosha D, Gon- zales-Siles L, Nordén R, et al. Carriage of penicil- lin-non-susceptible pneumococcci among children in northern Tanzania in the 13-valent pneumococcal vac-
cine era. *Int J Infect Dis* 2019; 81: 156-166.
43. Moyo SJ, Steinbakk M, Aboud S, Mkopi N, Kasumbi M, Blomberg B, et al. Penicillin resistance and serotype distribution of *Streptococcus pneumoniae* in nasopharyngeal carrier children under 5 years of age in Dar es Salaam, Tanzania. *J Med Microbiol* 2012; 61: 952-959.
44. Uddén F, Filipé M, Slotved HC, Yamba-Yamba L, Fuursted K, Pintar Kuatoko P, et al. Pneumococcal carriage among children aged 4 – 12 years in Angola 4 years after the introduction of a pneumococcal conjugate vaccine. *Vaccine* 2020; 38: 7928-7937.
45. Beheshti M, Jabalameli F, Feizabadi MM, Hahsemi FB, Beigverdi R, Emaneini M. Molecular characterization, antibiotic resistance pattern and capsular types of invasive *Streptococcus pneumoniae* isolated from clinical samples in Tehran, Iran. *BMC Microbiol* 2020; 20: 167.
46. Horácio AN, Silva-Costa C, Lopes E, Ramirez M, and Melo-Cristino J. Portuguese Group for the Study of Streptococcal Infections. Conjugate vaccine serotypes persist as major causes of non-invasive pneumococcal pneumonia in Portugal despite declines in serotypes 3 and 19A (2012-2015). *PLoS One* 2018; 13(1): e0206912.
47. Dewé TCM, D’aeth JC, and Croucher NJ. Genomic epidemiology of penicillin-non-susceptible *Streptococcus pneumoniae*. *Microb Genom* 2019; 5(10): e000305.
48. Zintgraff J, Gagetti P, Napoli D, Sanchez EluchansN, Irazu L, Moscoloni M, et al. Invasive *Streptococcus pneumoniae* isolates from pediatric population in Argentina for the period 2006–2019. Temporal progression of serotypes distribution and antibiotic resistance. *Vaccine* 2022; 40: 459-470.
49. Al-Jardani A, Al Rashdi A, Al Jaaidi A, Al Bulushi M, Al Mahrouri S, Al-Abri S, et al. Serotype distribution and antibiotic resistance among invasive *Streptococcus pneumoniae* from Oman post 13-valent vaccine introduction. *Int J Infect Dis* 2019; 85: 135-140.
50. Houri H, Tabatabaeei SR, Saei Y, Fallah F, Rahbar M, Karimi A. Distribution of capsular types and drug resistance patterns of invasive pediatric *Streptococcus pneumoniae* isolates in Teheran, Iran. *Int J Infect Dis* 2017; 57: 21-26.
51. Tsai YT, Lee YL, Lu MC, Shao PL, Lu PL, Cheng SH, et al. Nationwide surveillance of antimicrobial resistance in invasive isolates of *Streptococcus pneumoniae* in Taiwan from 2017 to 2019. *J Microbiol Immunol Infect* 2022; 55:215-224.
52. Pan F, Han L, Kong J, Wang C, Qin H, Xiao S, et al. Serotype distribution and antimicrobial resistance of *Streptococcus pneumoniae* causing noninvasive diseases in a Children’s hospital, Shanghai. *Braz J Infect Dis* 2015; 19: 141-145.
53. Amanda G, Tafroji W, Sutoyo DK, Burhan E, Haryanto B, Safari D. Serotype distribution and antimicrobial profile of *Streptococcus pneumoniae* isolated from adult patients with community-acquired pneumonia in Jakarta, Indonesia. *J Microbiol Immunol Infect* 2021; 54: 1175-1178.
54. Salsabila K, Paramaiswari WT, Amalia H, Ruyani A, Tafroji W, Winarti Y, et al. Nasopharyngeal carriage rate, serotype distribution, and antimicrobial susceptibility profile of *Streptococcus pneumoniae* isolated from children under five years old in Kotabaru, South Kalimantan, Indonesia. *J Microbiol Immunol Infect* 2021; S1684-1182(21)00138-9.
55. Manyahi J, Moyo S, Aboud S, Langeland N, Blomberg B. High rate of antimicrobial resistance and multiple mutations in the dihydrololate reductase gene among *Streptococcus pneumoniae* isolated from HIV-infected adults in a community setting in Tanzania. *J Glob Antimicrob Resist* 2020; 22: 749-753.
56. Kawaguchiya M, Urushibara N, Aung MS, Ito M, Takahashi A, Habadera S, et al. High prevalence of antimicrobial resistance in non-vaccine serotypes of non-invasive/colonization isolates of *Streptococcus pneumoniae*: A cross-sectional study eight years after the licensure of conjugate vaccine in Japan. *J Infect Public Health* 2020; 13: 1094-1100.